KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Alnylam Pharmaceuticals (ALNY) Enterprise Value (2016 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Enterprise Value for 16 consecutive years, with -$1.3 billion as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Enterprise Value rose 53.42% year-over-year to -$1.3 billion, compared with a TTM value of -$1.1 billion through Jun 2025, up 57.41%, and an annual FY2025 reading of -$1.3 billion, up 53.42% over the prior year.
  • Enterprise Value was -$1.3 billion for Q4 2025 at Alnylam Pharmaceuticals, down from -$1.1 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$536.3 million in Q1 2022 and bottomed at -$2.7 billion in Q4 2024.
  • Average Enterprise Value over 5 years is -$1.5 billion, with a median of -$1.1 billion recorded in 2025.
  • The sharpest move saw Enterprise Value tumbled 372.72% in 2021, then soared 67.6% in 2022.
  • Year by year, Enterprise Value stood at -$2.4 billion in 2021, then soared by 63.27% to -$870.7 million in 2022, then rose by 6.16% to -$817.1 million in 2023, then tumbled by 228.77% to -$2.7 billion in 2024, then skyrocketed by 53.42% to -$1.3 billion in 2025.
  • Business Quant data shows Enterprise Value for ALNY at -$1.3 billion in Q4 2025, -$1.1 billion in Q2 2025, and -$1.6 billion in Q1 2025.